

Electronic Supplementary information

Organo-NHC catalyzed domino addition approach for the selective synthesis of 5-butynylisoxazoles and subsequent Sonogashira coupling

Shravankumar Kankala,^a Sreekantha B Jonnalagadda,^{*a} and Chandra Sekhar Vasam^{*b,c}

^aSchool of Chemistry & Physics, University of Kwazulu-Natal, Westville Campus, Chiltern Hills, Durban-4000, South Africa. Fax: +27 31 260 3091; Tel: +27 31 260 7325/3090; E-mail: jonnalagaddas@ukzn.ac.za

^bDepartment of Chemistry, Satavahana University, Karimnagar, India.

^cDepartment of Pharmaceutical Chemistry, Telangana University, Nizamabad, India. Fax: +91-878-2255933; Tel: +91-9000285433; E-mail: vasamcs@yahoo.co.in

3. Experimental

General

All commercially available reagents were used without further purification. Reaction solvents were dried by standard methods before use. Purity of the compounds was checked by TLC using Merck 60F254 silica gel plates. Elemental analyses were obtained with an Elemental Analyser Perkin-Elmer 240C apparatus. IR spectra were recorded with a Perkin-Elmer 881 spectrometer. ^1H and ^{13}C NMR spectra were recorded with a Mercuryplus 400 spectrometer (operating at 400 MHz for ^1H and 100.58 MHz for ^{13}C); chemical shifts were referenced to TMS. EI (electron impact) mass spectra (at an ionising voltage of 70 eV) were obtained using a Shimadzu QP5050A quadrupole-based mass spectrometer.

General procedure for the synthesis of 5-butynylisoxazoles (**4a-l**):

To a suspension of magnesium turnings (8 mmol, 8 equiv) in anhydrous tetrahydrofuran (20 mL) added mercury(II) chloride (5 mg, 1% w/w of propargyl bromide) and propargyl bromide (80 wt % solution in toluene, 6 mmol, 6 equiv) in small portions slowly to generate a cloudy pale yellow solution of allenylmagnesium bromide. This was cooled to 0-5 °C and added with NHC precursor (1,3-Di-*tert*-butylimidazolium chloride (i)) (2 mmol). To this, a solution of *in situ* generated benzonitrile oxide (1 mmol), was added by maintaining the temperature between 0-5 °C under stirring. The reaction mass was allowed to stir for 5 minutes at room temperature. After this conversion, the mixture is quenched by addition of saturated solution of NH_4Cl (2 mL) and diluted with dichloromethane (20 mL). The organic layer was separated and the aqueous layer extracted with dichloromethane (2 x 20 mL). The combined organic layers were dried (anhydrous Na_2SO_4) and evaporated under reduced pressure to afford a crude product which was subjected to column chromatography (silica gel, 60-120 mesh, eluent; n-hexane/EtOAc gradient) to afford pure products (**4a-l**).

Spectral Data of Compounds (4a-l):

3-(4-Methoxyphenyl)-5-butynylisoxazole (4a). ^1H NMR (200 MHz, CDCl_3 , 25 °C): δ = 2.04 (s, 1H), 2.64 (t, 2H, J = 7.2 Hz), 3.02 (t, 2H, J = 7.2 Hz), 3.85 (s, 3H), 6.37 (s, 1H), 6.99 (d, 2H, J = 8.7 Hz, Ar-H), 7.51 (d, 2H, J = 8.7 Hz, Ar-H) ppm. ^{13}C NMR (100 MHz, CDCl_3 , 25 °C): δ = 17.14, 26.11, 55.32, 69.72, 82.15, 99.42, 114.36, 121.74, 128.21, 160.94, 162.05, 171.42 ppm. IR (KBr): = 3281, 2964, 2937, 2837, 1608, 1524, 1462, 1430, 1253, 1176, 1052, 840, 792, 659, 533 cm^{-1} . MS (EI, 70 eV): m/z (%) = 227 [M] $^+$. EA calcd (%) for $\text{C}_{14}\text{H}_{13}\text{NO}_2$ (227.09): calcd. C 73.99, H 5.77, N 6.16; found C 73.98, H 5.75, N 6.14.

3-(4-Methylphenyl)-5-butynylisoxazole (4b). ^1H NMR (200 MHz, CDCl_3 , 25 °C): δ = 2.04 (s, 1H), 2.28 (s, 3H), 2.64 (t, 2H, J = 7.2 Hz), 3.02 (t, 2H, J = 7.2 Hz), 6.37 (s, 1H), 6.99 (d, 2H, J = 8.7 Hz, Ar-H), 7.51 (d, 2H, J = 8.7 Hz, Ar-H) ppm. ^{13}C NMR (100 MHz, CDCl_3 , 25 °C): δ = 17.14, 19.24, 26.11, 69.72, 82.15, 99.44, 114.36, 121.72, 128.21, 160.94, 162.05, 171.46 ppm. IR (KBr): = 3281, 2964, 2937, 2835, 1608, 1520, 1462, 1430, 1253, 1176, 1052, 840, 792, 532 cm^{-1} . MS (EI, 70 eV): m/z (%) = 211 [M] $^+$. EA calcd (%) for $\text{C}_{14}\text{H}_{13}\text{NO}$ (211.10): calcd. C 79.59, H 6.20, N 6.63; found C 79.58, H 6.18, N 6.60.

3-(2-Nitrophenyl)-5-butynylisoxazole (4c). ^1H NMR (200 MHz, CDCl_3 , 25 °C): δ = 2.04 (s, 1H), 2.64 (t, 2H, J = 7.2 Hz), 3.02 (t, 2H, J = 7.2 Hz), 6.37 (s, 1H), 7.05 (m, 3H, Ar-H), 8.12 (m, 1H, Ar-H) ppm. ^{13}C NMR (100 MHz, CDCl_3 , 25 °C): δ = 17.14, 26.11, 69.72, 82.15, 99.42, 114.36, 125.55, 129.26, 160.94, 162.05, 171.42 ppm. IR (KBr): = 3281, 2964, 2932, 2837, 1610, 1524, 1450, 1430, 1253, 1176, 1052, 840, 792, 659, 533 cm^{-1} . MS (EI, 70 eV): m/z (%) = 242 [M] $^+$. EA calcd (%) for $\text{C}_{13}\text{H}_{10}\text{N}_2\text{O}_3$ (242.07): calcd. C 64.46, H 4.16, N 11.56; found C 64.45, H 4.13, N 11.55.

3-(4-Chlorophenyl)-5-butynylisoxazole (4d). ^1H NMR (200 MHz, CDCl_3 , 25 °C): δ = 2.04 (s, 1H), 2.64 (t, 2H, J = 7.2 Hz), 3.02 (t, 2H, J = 7.2 Hz), 6.37 (s, 1H), 6.99 (d, 2H, J = 6.7 Hz, Ar-H), 7.54 (d, 2H, J = 6.7 Hz, Ar-H) ppm. IR (KBr): = 3281, 2964, 2937,

2837, 1606, 1524, 1460, 1430, 1253, 1176, 1052, 840, 792, 659, 533 cm^{-1} . MS (EI, 70 eV): m/z (%) = 231 $[\text{M}]^+$. EA calcd (%) for $\text{C}_{13}\text{H}_{10}\text{ClNO}$ (231.05): calcd. C 67.40, H 4.35, N 6.05; found C 67.38, H 4.33, N 6.05.

3-phenyl-5-butynylisoxazole (4e). ^1H NMR (200 MHz, CDCl_3 , 25 $^\circ\text{C}$): δ = 2.04 (s, 1H), 2.64 (t, 2H, J = 7.2 Hz), 3.02 (t, 2H, J = 7.2 Hz), 6.37 (s, 1H), 6.84-7.10 (m, 5H, Ar-H) ppm. IR (KBr): = 3281, 2964, 2937, 2837, 1608, 1524, 1462, 1430, 1253, 1176, 1052, 840, 792, 659, 533 cm^{-1} . MS (EI, 70 eV): m/z (%) = 197 $[\text{M}]^+$. EA calcd (%) for $\text{C}_{13}\text{H}_{11}\text{NO}$ (197.08): calcd. C 79.16, H 5.62, N 7.10; found C 79.12, H 5.60, N 7.08.

3-(4-Nitrophenyl)-5-butynylisoxazole (4f). ^1H NMR (200 MHz, CDCl_3 , 25 $^\circ\text{C}$): δ = 2.04 (s, 1H), 2.64 (t, 2H, J = 7.2 Hz), 3.02 (t, 2H, J = 7.2 Hz), 6.37 (s, 1H), 6.94 (d, 2H, J = 8.7 Hz, Ar-H), 8.101 (d, 2H, J = 8.7 Hz, Ar-H) ppm. IR (KBr): = 3285, 2964, 2937, 2837, 1608, 1520, 1462, 1434, 1250, 1176, 1052, 840, 792, 659, 533 cm^{-1} . MS (EI, 70 eV): m/z (%) = 242 $[\text{M}]^+$. EA calcd (%) for $\text{C}_{13}\text{H}_{10}\text{N}_2\text{O}_3$ (242.07): calcd. C 64.46, H 4.16, N 11.56; found C 64.45, H 4.13, N 11.54.

3-(4-Fluorophenyl)-5-butynylisoxazole (4g). ^1H NMR (200 MHz, CDCl_3 , 25 $^\circ\text{C}$): δ = 2.04 (s, 1H), 2.64 (t, 2H, J = 7.2 Hz), 3.02 (t, 2H, J = 7.2 Hz), 6.37 (s, 1H), 6.94 (d, 2H, J = 8.1 Hz, Ar-H), 7.56 (d, 2H, J = 8.1 Hz, Ar-H) ppm. IR (KBr): = 3277, 2964, 2937, 2832, 1606, 1460, 1430, 1253, 1176, 1052, 842, 796, 659, 530 cm^{-1} . MS (EI, 70 eV): m/z (%) = 215 $[\text{M}]^+$. EA calcd (%) for $\text{C}_{13}\text{H}_{10}\text{FNO}$ (215.07): calcd. C 72.55, H 4.68, N 6.51; found C 72.52, H 4.66, N 6.50.

3-(2,3-Dimethoxyphenyl)-5-butynylisoxazole (4h). ^1H NMR (200 MHz, CDCl_3 , 25 $^\circ\text{C}$): δ = 2.04 (s, 1H), 2.64 (t, 2H, J = 7.2 Hz), 3.02 (t, 2H, J = 7.2 Hz), 3.62 (s, 3H), 3.85 (s, 3H), 6.38 (s, 1H), 6.99-7.10 (m, 3H, Ar-H) ppm. IR (KBr): = 3281, 2960, 2937, 2837, 1612, 1528, 1462, 1432, 1253, 1176, 1052, 845, 784, 655 cm^{-1} . MS (EI, 70 eV): m/z (%) = 257 $[\text{M}]^+$. EA calcd (%) for $\text{C}_{15}\text{H}_{15}\text{NO}_3$ (257.11): calcd. C 70.02, H 5.88, N 5.44; found C 69.96, H 5.86, N 5.42.

3-(2-Naphthyl)-5-butynylisoxazole (4i). ^1H NMR (200 MHz, CDCl_3 , 25 °C): δ = 2.04 (s, 1H), 2.64 (t, 2H, J = 7.2 Hz), 3.02 (t, 2H, J = 7.2 Hz), 6.35 (s, 1H), 7.21-7.56 (m, 7H, Ar-H) ppm. IR (KBr): = 3280, 2964, 2937, 2834, 1608, 1524, 1462, 1430, 1253, 1176, 1052, 792, 644, 530 cm^{-1} . MS (EI, 70 eV): m/z (%) = 247 $[\text{M}]^+$. EA calcd (%) for $\text{C}_{17}\text{H}_{13}\text{NO}$ (247.10): calcd. C 82.57, H 5.30, N 5.66; found C 82.54, H 5.28, N 5.64.

3-(4-Cyanophenyl)-5-butynylisoxazole (4j). ^1H NMR (200 MHz, CDCl_3 , 25 °C): δ = 2.06 (s, 1H), 2.65 (t, 2H, J = 7.2 Hz), 3.04 (t, 2H, J = 7.2 Hz), 6.37 (s, 1H), 7.12 (d, 2H, J = 6.7 Hz, Ar-H), 7.36 (d, 2H, J = 6.7 Hz, Ar-H) ppm. IR (KBr): = 3275, 2964, 2937, 2832, 1606, 1454, 1432, 1253, 1176, 1056, 842, 796, 664, 530 cm^{-1} . MS (EI, 70 eV): m/z (%) = 222 $[\text{M}]^+$. EA calcd (%) for $\text{C}_{14}\text{H}_{10}\text{N}_2\text{O}$ (222.08): calcd. C 75.66, H 4.54, N 12.60; found C 75.64, H 4.52, N 12.58.

3-(3-Bromo-4-methoxyphenyl)-5-butynylisoxazole (4k). ^1H NMR (200 MHz, CDCl_3 , 25 °C): δ = 2.04 (s, 1H), 2.64 (t, 2H, J = 7.2 Hz), 3.02 (t, 2H, J = 7.2 Hz), 6.38 (s, 1H), 6.82 (d, 1H, Ar-H), 7.56 (d, 1H, Ar-H), 7.68 (s, 1H, Ar-H) ppm. IR (KBr): = 3275, 2965, 2932, 2832, 1604, 1460, 1430, 1255, 1176, 1055, 842, 796, 650 cm^{-1} . MS (EI, 70 eV): m/z (%) = 305 $[\text{M}]^+$. EA calcd (%) for $\text{C}_{14}\text{H}_{12}\text{BrNO}_2$ (305.01): calcd. C 54.92, H 3.95, N 4.58; found C 54.90, H 3.92, N 4.56.

3-(4-Hydroxyphenyl)-5-butynylisoxazole (4l). ^1H NMR (200 MHz, CDCl_3 , 25 °C): δ = 2.04 (s, 1H), 2.64 (t, 2H, J = 7.2 Hz), 3.02 (t, 2H, J = 7.2 Hz), 5.12 (s, 1H), 6.37 (s, 1H), 6.83 (d, 2H, J = 7.2 Hz, Ar-H), 7.44 (d, 2H, J = 7.2 Hz, Ar-H) ppm. IR (KBr): = 3524, 3270, 2962, 2930, 2832, 1610, 1462, 1430, 1253, 1176, 1052, 845, 795, 659 cm^{-1} . MS (EI, 70 eV): m/z (%) = 213 $[\text{M}]^+$. EA calcd (%) for $\text{C}_{13}\text{H}_{11}\text{NO}_2$ (213.08): calcd. C 73.22, H 5.20, N 6.57; found C 73.20, H 5.18, N 6.53.

General procedure for Sonogashira cross-coupling. In a typical procedure, to a suspension of $\text{Pd}(\text{OAc})_2$ (0.03 mmol) and Ag(I)-NHC (NHC = 1,3-Di-*tert*-butylimidazolin-2-ylidene (i)) (0.03 mmol) was dissolved in DCM (10 mL). Then, the indicated amount of above dichloromethane solution was added to a mixture of aryl

iodides (1 mmol), 5-butynylisoxazoles (1.2 mmol), pyrrolidine (3 mmol, 3 equiv), and DCM (15 mL). Then, the mixture was stirred at room temperature for 2 h to form the desired coupled products. Complete consumption of starting material was judged by TLC and GC analysis. After, the mixture was filtered and evaporated, the residue was purified by column chromatography (silica gel, 60-120 mesh, eluent; n-hexane/EtOAc (8:2) gradient) to afford the desired coupled product (**6a-o**).

Spectral Data of Compounds (6a-o):

3-(4-methoxyphenyl)-5-(4-p-tolylbut-3-ynyl)isoxazole (6a). ¹H NMR (400 MHz, CDCl₃, 25 °C): δ = 2.45 (s, 3H), 2.66 (t, 2 H, $J=6.9$ Hz), 3.08 (t, 2 H, $J=6.9$ Hz), 3.82 (s, 3H), 6.43 (s, 1 H), 6.82 (d, 2H, Ar-H), 7.20 (d, 2H, Ar-H), 7.32-7.39 (m, 4H, Ar-H) ppm. ¹³C NMR (100 MHz, CDCl₃, 25 °C): δ = 17.40, 21.82, 31.24, 36.92, 84.94, 86.82, 93.15, 114.52, 119.34, 119.82, 126.30, 129.81, 131.42, 138.92, 157.60, 159.45, 172.50 ppm. IR (KBr): = 3080, 2964, 2937, 2837, 1980, 1866, 1612, 1524, 1462, 1273, 1256, 1166, 1052, 948, 840, 792, 788, 659, 533cm⁻¹. MS (EI, 70 eV): m/z (%) = 318 [M + H]⁺. EA calcd (%) for C₂₁H₁₉NO₂ (317.03): calcd. C 79.47, H 6.03, N 4.41; found C 79.45, H 6.01, N 4.40.

3-(4-methoxyphenyl)-5-(4-(4-methoxyphenyl)but-3-ynyl)isoxazole (6b). ¹H NMR (400 MHz, CDCl₃, 25 °C): δ = 2.66 (t, 2 H, $J=6.9$ Hz), 3.08 (t, 2 H, $J=6.9$ Hz), 3.82 (s, 6H), 6.43 (s, 1H), 6.75-6.82 (m, 4H, Ar-H), 7.32-7.39 (m, 4H, Ar-H) ppm. ¹³C NMR (100 MHz, CDCl₃, 25 °C): δ = 17.40, 31.22, 36.19, 54.23, 85.21, 86.81, 92.32, 113.52, 114.54, 114.24, 120.21, 127.30, 134.64, 158.34, 159.52, 160.15, 172.34 ppm. IR (KBr): = 3080, 2964, 2937, 2837, 1612, 1524, 1462, 1273, 1256, 1166, 1052, 948, 840, 792, 788, 659, 533cm⁻¹. MS (EI, 70 eV): m/z (%) = 334 [M + H]⁺. EA calcd (%) for C₂₁H₁₉NO₃ (333.11): calcd. C 75.66, H 5.74, N 4.20; found C 75.64, H 5.73, N 4.17.

3-(4-methoxyphenyl)-5-(4-phenylbut-3-ynyl)isoxazole (6c). ¹H NMR (400 MHz, CDCl₃, 25 °C): δ = 2.66 (t, 2 H, $J=6.9$ Hz), 3.08 (t, 2 H, $J=6.9$ Hz), 3.82 (s, 3H), 6.43 (s, 1H), 6.85 (d, 2 H, Ar-H), 7.05-7.12 (m, 5H, Ar-H), 7.61 (d, 2H, Ar-H) ppm. ¹³C NMR

(100 MHz, CDCl₃, 25 °C): δ = 17.45, 28.33, 39.20, 72.61, 89.15, 99.42, 114.38, 121.70, 122.42, 126.44, 129.86, 131.82, 159.22, 160.92, 162.10, 171.44 ppm. IR (KBr): = 3080, 2964, 2937, 2837, 1612, 1524, 1462, 1298, 1256, 1176, 1052, 948, 840, 792, 788, 659, 533cm⁻¹. MS (EI, 70 eV): m/z (%) = 304 [M + H]⁺. EA calcd (%) for C₂₀H₁₇NO₂ (303.00): calcd. C 79.19, H 5.65, N 4.62; found C 79.17, H 5.64, N 4.61.

3-(4-methoxyphenyl)-5-(4-(4-nitrophenyl)but-3-ynyl)isoxazole (6d). ¹H NMR (400 MHz, CDCl₃, 25 °C): δ = 2.66 (t, 2 H, J =6.9 Hz), 3.08 (t, 2 H, J =6.9 Hz), 3.82 (s, 3H), 6.43 (s, 1H), 6.82 (d, 2H, Ar-H), 7.32-7.39 (m, 4H, Ar-H), 8.26 (d, 2H, Ar-H) ppm. ¹³C NMR (100 MHz, CDCl₃, 25 °C): δ = 17.44, 31.42, 37.82, 85.15, 87.23, 93.60, 114.32, 120.14, 123.60, 126.84, 132.42, 132.80, 148.24, 159.35, 159.60, 173.42 ppm. IR (KBr): = 3102, 3080, 2964, 2917, 2832, 1612, 1520, 1462, 1273, 1256, 1162, 1054, 948, 842, 792, 788, 659, 533 cm⁻¹. MS (EI, 70 eV): m/z (%) = 349 [M + H]⁺. EA calcd (%) for C₂₀H₁₆N₂O₄ (348.12): calcd. C 68.96, H 4.63, N 8.04; found C 68.94, H 4.62, N 8.01.

1-(4-(4-(3-(4-methoxyphenyl)isoxazol-5-yl)but-1-ynyl)phenyl)ethanone (6e). ¹H NMR (400 MHz, CDCl₃, 25 °C): δ = 2.56 (s, 3H), 2.66 (t, 2 H, J =6.9 Hz), 3.08 (t, 2 H, J =6.9 Hz), 3.82 (s, 3H), 6.43 (s, 1H), 6.82 (d, 2H, Ar-H), 7.32-7.39 (m, 4H, Ar-H), 7.89 (d, 2H, Ar-H) ppm. ¹³C NMR (100 MHz, CDCl₃, 25 °C): δ = 17.45, 24.82, 31.20, 37.31, 85.24, 88.65, 93.60, 114.32, 120.41, 124.20, 126.32, 129.84, 132.42, 137.20, 159.54, 160.32, 172.40, 195.82 ppm. IR (KBr): = 3080, 2964, 2937, 2837, 1696, 1524, 1462, 1273, 1256, 1166, 1052, 948, 840, 792, 788, 659, 533cm⁻¹. MS (EI, 70 eV): m/z (%) = 346 [M + H]⁺. EA calcd (%) for C₂₂H₁₉NO₃ (345.02): calcd. C 76.50, H 5.54, N 4.06; found C 76.48, H 5.52, N 4.05.

3-phenyl-5-(4-*p*-tolylbut-3-ynyl)isoxazole (6f). ¹H NMR (400 MHz, CDCl₃, 25 °C): δ = 2.45 (s, 3H), 2.66 (t, 2 H, J =6.9 Hz), 3.08 (t, 2 H, J =6.9 Hz), 6.43 (s, 1H), 7.13 (d, 2H, Ar-H), 7.24-7.32 (m, 5H, Ar-H), 7.61 (d, 2H, Ar-H) ppm. ¹³C NMR (100 MHz, CDCl₃, 25 °C): δ = 17.32, 22.41, 30.80, 85.26, 88.22, 93.21, 119.24, 123.81, 125.16, 125.28, 126.22, 130.27, 131.48, 140.52, 159.14, 172.53 ppm. IR (KBr): = 3080, 2975, 2965, 2938, 2918, 1605, 1527, 1495, 1466, 1298, 1256, 1176, 1052, 948, 840, 792, 788, 659,

533cm⁻¹. MS (EI, 70 eV): m/z (%) = 288 [M + H]⁺. EA calcd (%) for C₂₀H₁₇NO (287.09): calcd. C 83.59, H 5.96, N 4.87; found C 83.57, H 5.92, N 4.85.

5-(4-(4-methoxyphenyl)but-3-ynyl)-3-phenylisoxazole (6g). ¹H NMR (400 MHz, CDCl₃, 25 °C): δ = 2.66 (t, 2 H, $J=6.9$ Hz), 3.08 (t, 2 H, $J=6.9$ Hz), 3.82 (s, 3H), 6.43 (s, 1H), 6.84 (d, 2H, Ar-H), 7.24-7.32 (m, 5H, Ar-H), 7.61 (d, 2H, Ar-H) ppm. ¹³C NMR (100 MHz, CDCl₃, 25 °C): δ = 17.34, 29.62, 55.60, 85.22, 87.62, 93.20, 113.64, 115.82, 123.24, 125.42, 125.81, 126.35, 135.84, 159.20, 162.21, 173.10 ppm. IR (KBr): = 3082, 2964, 2937, 2837, 1610, 1527, 1459, 1422, 1298, 1256, 1176, 1052, 948, 840, 792, 788, 659, 533cm⁻¹. MS (EI, 70 eV): m/z (%) = 304 [M + H]⁺. EA calcd (%) for C₂₀H₁₇NO₂ (303.00): calcd. C 79.19, H 5.65, N 4.62; found C 79.17, H 5.64, N 4.61.

3-phenyl-5-(4-phenylbut-3-ynyl)isoxazole (6h). ¹H NMR (400 MHz, CDCl₃, 25 °C): δ = 2.66 (t, 2 H, $J=6.9$ Hz), 3.08 (t, 2 H, $J=6.9$ Hz), 6.43 (s, 1 H), 6.99-7.12 (m, 4H, Ar-H), 7.31-7.39 (m, 2H, Ar-H) 7.42-7.51 (m, 4H, Ar-H) ppm. ¹³C NMR (100 MHz, CDCl₃, 25 °C): δ = 17.42, 29.60, 85.24, 87.65, 93.72, 123.40, 123.82, 124.12, 125.27, 126.32, 128.50, 128.16, 131.28, 159.52, 171.82 ppm. IR (KBr): = 3082, 2964, 2937, 2837, 1610, 1527, 1459, 1422, 948, 840, 792, 788, 659, 533cm⁻¹. MS (EI, 70 eV): m/z (%) = 274 [M + H]⁺. EA calcd (%) for C₁₉H₁₅NO (273.02): calcd. C 83.49, H 5.53, N 5.12; found C 83.48, H 5.51, N 5.11.

5-(4-(4-nitrophenyl)but-3-ynyl)-3-phenylisoxazole (6i). ¹H NMR (400 MHz, CDCl₃, 25 °C): δ = 2.66 (t, 2 H, $J=6.9$ Hz), 3.08 (t, 2 H, $J=6.9$ Hz), 6.43 (s, 1 H), 7.24-7.32 (m, 5H, Ar-H), 7.61 (d, 2H, Ar-H) 8.22 (d, 2H, Ar-H) ppm. ¹³C NMR (100 MHz, CDCl₃, 25 °C): δ = 17.34, 31.40, 85.12, 86.72, 93.51, 122.80, 123.64, 124.34, 125.70, 126.44, 131.80, 132.32, 148.54, 159.22, 173.24 ppm. IR (KBr): = 3100, 3080, 2975, 2965, 1605, 1523, 1495, 1347, 1298, 1256, 1176, 1052, 948, 854, 792, 788, 659, 533cm⁻¹. MS (EI, 70 eV): m/z (%) = 319 [M + H]⁺. EA calcd (%) for C₁₉H₁₄N₂O₃ (318.10): calcd. C 71.69, H 4.43, N 8.80; found C 71.65, H 4.41, N 8.78.

1-(4-(4-(3-phenylisoxazol-5-yl)but-1-ynyl)phenyl)ethanone (6j). ¹H NMR (400 MHz, CDCl₃, 25 °C): δ = 2.52 (s, 3H), 2.66 (t, 2 H, *J*=6.9 Hz), 3.08 (t, 2 H, *J*=6.9 Hz), 6.43 (s, 1 H), 7.24-7.32 (m, 5H, Ar-H), 7.61 (d, 2H, Ar-H) 7.92 (d, 2H, Ar-H) ppm. ¹³C NMR (100 MHz, CDCl₃, 25 °C): δ = 17.42, 26.41, 31.20, 86.16, 87.92, 92.32, 123.80, 124.64, 125.42, 125.81, 126.20, 129.32, 131.19, 137.15, 159.15, 172.61, 193.30 ppm. IR (KBr): = 3080, 2975, 2963, 2918, 1697, 1605, 1527, 1495, 1466, 1298, 1256, 1176, 1050, 946, 840, 792, 788, 659, 533cm⁻¹. MS (EI, 70 eV): *m/z* (%) = 316 [M + H]⁺. EA calcd (%) for C₂₁H₁₇NO₂ (315.03): calcd. C 79.98, H 5.43, N 4.44; found C 79.97, H 5.42, N 4.41.

3-(4-nitrophenyl)-5-(4-p-tolylbut-3-ynyl)isoxazole (6k). ¹H NMR (400 MHz, CDCl₃, 25 °C): δ = 2.43 (s, 3H), 2.66 (t, 2 H, *J*=6.9 Hz), 3.08 (t, 2 H, *J*=6.9 Hz), 6.43 (s, 1H), 7.12 (d, 2H, Ar-H), 7.32-7.39 (m, 4H, Ar-H), 8.25 (d, 2H, Ar-H) ppm. ¹³C NMR (100 MHz, CDCl₃, 25 °C): δ = 17.42, 21.80, 31.22, 85.24, 87.10, 93.12, 113.84, 115.20, 126.31, 127.20, 132.47, 134.02, 148.45, 158.13, 160.21, 172.18 ppm. IR (KBr): = 3100, 3080, 2964, 2917, 2832, 1615, 1521, 1462, 1273, 1254, 1162, 1054, 936, 842, 792, 788, 659, 538cm⁻¹. MS (EI, 70 eV): *m/z* (%) = 333 [M + H]⁺. EA calcd (%) for C₂₀H₁₆N₂O₃ (332.10): calcd. C 72.28, H 4.85, N 8.43; found C 72.25, H 4.84, N 8.41.

5-(4-(4-methoxyphenyl)but-3-ynyl)-3-(4-nitrophenyl)isoxazole (6l). ¹H NMR (400 MHz, CDCl₃, 25 °C): δ = 2.66 (t, 2 H, *J*=6.9 Hz), 3.08 (t, 2 H, *J*=6.9 Hz), 3.82 (s, 3H), 6.43 (s, 1H), 6.82 (d, 2H, Ar-H), 7.32-7.39 (m, 4H, Ar-H), 8.25 (d, 2H, Ar-H) ppm. ¹³C NMR (100 MHz, CDCl₃, 25 °C): δ = 17.42, 31.20, 54.64, 85.26, 86.81, 93.20, 113.18, 115.42, 126.53, 127.10, 132.70, 134.12, 148.24, 158.30, 160.21, 172.84 ppm. IR (KBr): = 3100, 3080, 2964, 2917, 2832, 1613, 1525, 1462, 1273, 1254, 1162, 1054, 936, 842, 790, 788, 659, 533cm⁻¹. MS (EI, 70 eV): *m/z* (%) = 349 [M + H]⁺. EA calcd (%) for C₂₀H₁₆N₂O₄ (348.12): calcd. C 68.96, H 4.63, N 8.04; found C 68.94, H 4.62, N 8.01.

3-(4-nitrophenyl)-5-(4-phenylbut-3-ynyl)isoxazole (6m). ¹H NMR (400 MHz, CDCl₃, 25 °C): δ = 2.66 (t, 2 H, *J*=6.9 Hz), 3.08 (t, 2 H, *J*=6.9 Hz), 6.43 (s, 1H), 7.24-7.32 (m, 5H, Ar-H), 7.61 (d, 2H, Ar-H), 8.24 (d, 2H, Ar-H) ppm. ¹³C NMR (100 MHz, CDCl₃, 25 °C): δ = 17.42, 31.22, 85.24, 88.61, 93.10, 124.24, 126.35, 127.83, 128.42, 128.62,

129.80, 132.40, 149.52, 160.32, 172.40 ppm. IR (KBr): = 3108, 3082, 2964, 2937, 1608, 1527, 1459, 1298, 1256, 1176, 1052, 948, 834, 790, 782, 659, 533 cm^{-1} . MS (EI, 70 eV): m/z (%) = 319 [M + H]⁺. EA calcd (%) for C₁₉H₁₄N₂O₃ (318.10): calcd. C 71.69, H 4.43, N 8.80; found C 71.65, H 4.41, N 8.78.

3-(4-nitrophenyl)-5-(4-(4-nitrophenyl)but-3-ynyl)isoxazole (6n). ¹H NMR (400 MHz, CDCl₃, 25 °C): δ = 2.66 (t, 2 H, J =6.9 Hz), 3.08 (t, 2 H, J =6.9 Hz), 6.43 (s, 1H), 7.78-7.84 (m, 4H, Ar-H), 8.30-8.39 (m, 4H, Ar-H) ppm. ¹³C NMR (100 MHz, CDCl₃, 25 °C): δ = 17.44, 31.20, 85.25, 87.10, 93.21, 123.18, 126.30, 127.10, 129.82, 130.22, 132.72, 148.35, 148.92, 158.34, 172.81 ppm. IR (KBr): = 3100, 3080, 2964, 2917, 2832, 1521, 1462, 1273, 1236, 1054, 936, 842, 790, 788, 652, 525 cm^{-1} . MS (EI, 70 eV): m/z (%) = 364 [M + H]⁺. EA calcd (%) for C₁₉H₁₃N₃O₅ (363.05): calcd. C 62.81, H 3.61, N 11.57; found C 62.79, H 3.58, N 11.56.

1-(4-(4-(3-(4-nitrophenyl)isoxazol-5-yl)but-1-ynyl)phenyl)ethanone (6o). ¹H NMR (400 MHz, CDCl₃, 25 °C): δ = 2.51 (s, 3H), 2.66 (t, 2 H, J =6.9 Hz), 3.08 (t, 2 H, J =6.9 Hz), 6.43 (s, 1H), 7.35-7.44 (m, 4H, Ar-H), 7.64 (d, 2H, Ar-H), 8.27 (d, 2H, Ar-H) ppm. ¹³C NMR (100 MHz, CDCl₃, 25 °C): δ = 17.42, 24.81, 31.20, 85.24, 88.62, 93.65, 124.34, 126.42, 127.20, 129.84, 130.62, 132.40, 137.21, 149.14, 158.17, 172.42, 194.82 ppm. IR (KBr): = 3100, 3080, 2960, 2917, 2832, 1694, 1521, 1460, 1273, 1236, 1050, 930, 842, 790, 768, 652, 542 cm^{-1} . MS (EI, 70 eV): m/z (%) = 361 [M + H]⁺. EA calcd (%) for C₂₁H₁₆N₂O₄ (360.02): calcd. C 69.99, H 4.48, N 7.77; found C 69.98, H 4.46, N 7.75.